<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of croup</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of croup</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of croup</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles R Woods, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna H Messner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joshua Nagler, MD, MHPEd</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Croup (laryngotracheitis) is a respiratory illness characterized by inspiratory stridor, barking cough, and hoarseness. It typically occurs in young children and is caused by viruses, particularly parainfluenza virus. (See  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis"</a>.)</p><p>Most children with croup who seek medical attention have a mild, self-limited illness and can be successfully managed as outpatients. Children with moderate to severe symptoms require full evaluation and treatment in the office or emergency department (ED) setting  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>). (See <a class="local">'Severity assessment'</a> below.)</p><p>The approach to the management of croup will be discussed below. The clinical features, evaluation, and diagnosis of croup are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">SEVERITY ASSESSMENT</span></p><p class="headingAnchor" id="H96554194"><span class="h2">Telephone triage</span><span class="headingEndMark"> — </span>When assessing patients by phone, the health care provider must distinguish children who need immediate medical attention or further evaluation from those who can be managed at home. Children who need further evaluation include those who have  (<a class="graphic graphic_algorithm graphicRef141709" href="/z/d/graphic/141709.html" rel="external">algorithm 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Stridor at rest</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid progression of symptoms (ie, symptoms of upper airway obstruction after less than 12 hours of illness)</p><p class="bulletIndent1"><span class="glyph">●</span>Inability to tolerate oral fluids</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying known airway abnormality (eg, subglottic stenosis, subglottic hemangioma, previous intubation)</p><p class="bulletIndent1"><span class="glyph">●</span>Previous episodes of moderate to severe croup</p><p class="bulletIndent1"><span class="glyph">●</span>Medical conditions that predispose to respiratory failure (eg, neuromuscular disorders or bronchopulmonary dysplasia)</p><p class="bulletIndent1"><span class="glyph">●</span>Parental concern that cannot be relieved by reassurance</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged symptoms (more than three to seven days) or an atypical course (perhaps indicating an alternative diagnosis) (see  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Differential diagnosis'</a>)</p><p></p><p>Patients who are assessed by phone and are determined to have mild symptoms and none of the above indications for further evaluation can be managed at home. (See <a class="local">'Home treatment'</a> below.)</p><p class="headingAnchor" id="H73606114"><span class="h2">Croup severity score</span><span class="headingEndMark"> — </span>When the child is seen in the office or emergency department (ED), croup severity is assessed by examining the child and using a clinical scoring system. There are a number of validated croup scoring systems. The Westley croup score has been the most extensively studied [<a href="#rid1">1</a>]. The Westley croup score is summarized in the table  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>). The score can be determined using the croup severity score calculator (<a class="calc calc_patient" href="/z/d/html/105432.html" rel="external">calculator 1</a>). Additional details about the severity assessment are provided separately. (See  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Severity assessment'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">MILD CROUP</span><span class="headingEndMark"> — </span>Children with mild symptoms (Westley croup score of ≤2  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>) (<a class="calc calc_patient" href="/z/d/html/105432.html" rel="external">calculator 1</a>)) should be treated symptomatically with fever reduction and oral fluids. Many such children can be managed by phone, provided that none of the criteria for further evaluation described above are present. (See <a class="local">'Telephone triage'</a> above.)</p><p class="headingAnchor" id="H8"><span class="h2">Home treatment</span><span class="headingEndMark"> — </span>The caregivers of children with mild croup who are managed at home should be instructed in provision of supportive care, including mist, antipyretics, and encouragement of fluid intake.</p><p>Caregivers may try sitting with the child in a bathroom filled with steam generated by running hot water from the shower to improve symptoms. This may help reassure parents/caregivers that "something" is being done to reverse the symptoms, and anecdotal evidence supports some benefit with this measure.</p><p>Exposure to cold night air also may lessen symptoms of mild croup, although this has never been systematically studied. If parents/caregivers wish to use humidifiers at home, only those that produce mist at room temperature should be used to avoid the risk of burns from steam or the heating element.</p><p>Instructions should be provided to the caregivers regarding when to seek medical attention, including watching for [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stridor at rest</p><p class="bulletIndent1"><span class="glyph">●</span>Difficulty breathing</p><p class="bulletIndent1"><span class="glyph">●</span>Pallor or cyanosis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe coughing spells</p><p class="bulletIndent1"><span class="glyph">●</span>Drooling or difficulty swallowing</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening course</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent or high fever</p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged symptoms (longer than seven days)</p><p class="bulletIndent1"><span class="glyph">●</span>Suprasternal retractions</p><p></p><p>Caregivers also should be provided with guidance regarding when it is safe for them to drive the child to the emergency department (ED) and when they should activate emergency medical services. Transportation by emergency medical services is appropriate for children who are severely agitated, pale or cyanotic, struggling to breathe, or lethargic [<a href="#rid2">2</a>].</p><p>Patients who are managed at home should receive a follow-up phone call within 24 hours.</p><p class="headingAnchor" id="H9"><span class="h2">Outpatient treatment</span><span class="headingEndMark"> — </span>For children with mild croup who are seen in the outpatient setting, we suggest a single dose of oral <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> (0.15 to 0.6 mg/kg, maximum dose 16 mg) or oral <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> (1 mg/kg)  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>). Randomized controlled trials in children with mild croup have demonstrated that treatment with a single dose of oral glucocorticoid shortens the duration of symptoms and reduces return visits [<a href="#rid3">3,4</a>]. (See <a class="local">'Glucocorticoids'</a> below.)</p><p>An alternative approach is supportive care alone with anticipatory guidance about potential worsening and instructions on when to seek care or return for follow-up.</p><p>Treatment with nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> is not necessary for management of mild croup.</p><p>Children with mild croup who are tolerating fluids and have not received nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> can be sent home after specific follow-up (which may occur by phone) has been arranged and the caregiver has received instructions regarding home care and indications to seek medical attention, as described above. (See <a class="local">'Home treatment'</a> above.)</p><p class="headingAnchor" id="H10"><span class="h1">MODERATE TO SEVERE CROUP</span></p><p class="headingAnchor" id="H96554336"><span class="h2">Setting and pace of treatment</span><span class="headingEndMark"> — </span>The appropriate treatment setting depends upon the severity of symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with moderate croup (Westley croup score 3 to 7; stridor at rest and mild to moderate retractions but no or little distress or agitation  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>) (<a class="calc calc_patient" href="/z/d/html/105432.html" rel="external">calculator 1</a>)) should be evaluated in the emergency department (ED) or office, provided that the office is equipped to handle acute upper airway obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children with severe croup (Westley croup score ≥8; stridor at rest and marked retractions with agitation, lethargy, or cyanosis  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>) (<a class="calc calc_patient" href="/z/d/html/105432.html" rel="external">calculator 1</a>)) should be evaluated in the ED as they require prompt therapy, monitoring, and supportive care.</p><p></p><p>In children with severe croup, any increase in agitation or crying may worsen airway obstruction. The parent or caregiver should be encouraged to hold and comfort the child. Nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> should be administered as quickly as possible, as described below (see <a class="local">'Initial treatment'</a> below). In the meantime, health care providers should continuously observe the child and be prepared to provide additional respiratory support if the condition worsens  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>). (See <a class="local">'Respiratory care'</a> below.)</p><p class="headingAnchor" id="H95636"><span class="h2">Initial treatment</span><span class="headingEndMark"> — </span>Initial treatment of moderate to severe croup includes <strong>all</strong> of the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dexamethasone</strong> – We recommend glucocorticoid therapy for all children with moderate to severe croup. <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> (0.6 mg/kg, maximum of 16 mg) is generally the preferred glucocorticoid in this setting. Dexamethasone should be administered by the least invasive route possible: oral if oral intake is tolerated, intravenous (IV) if IV access has been established, or intramuscular (IM) if oral intake is not tolerated and IV access has not been established. The oral preparation of dexamethasone (1 mg/mL) has an unpleasant taste. Solutions for injection are more concentrated (4 mg/mL or 10 mg/mL) and can be given orally mixed with syrup [<a href="#rid2">2,5</a>]. Alternatively, oral tablets can be crushed and mixed with syrup or pureed food. A single dose of nebulized <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> (2 mg [2 mL solution] via nebulizer) is an alternative option, particularly for children who are vomiting and who lack IV access [<a href="#rid2">2,6,7</a>]. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nebulized </strong><strong>epinephrine</strong> – We recommend nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> in all patients with moderate to severe croup. Dosing and administration are as follows (see <a class="local">'Nebulized epinephrine'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Racemic <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>: 0.05 mL/kg per dose (maximum of 0.5 mL) of a 2.25% solution diluted to 3 mL total volume with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> (in the United States and some other countries, single-use preservative-free bullets [ampules] of racemic epinephrine for nebulized administration are commercially available).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>L-epinephrine: 0.5 mL/kg per dose (maximum of 5 mL) of a 1 mg/mL (1:1000) preservative-free solution (this is the parenteral preparation of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> used for intramuscular (IM) injection [eg, for anaphylaxis]).</p><p></p><p class="bulletIndent1">The drug is administered by nebulizer over 15 minutes. Use of either product is acceptable and may be determined by availability and institutional protocol. Nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> has an onset of effect within 10 minutes </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong>, including oxygen or humidified air as needed, antipyretics, and encouragement of fluid intake. (See <a class="local">'Supportive care'</a> below.)</p><p></p><p class="headingAnchor" id="H94481"><span class="h2">Observation and disposition</span></p><p class="headingAnchor" id="H3572678756"><span class="h3">Response to treatment</span><span class="headingEndMark"> — </span>Patients who receive nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> should be observed for three to four hours after initial treatment. The need for additional intervention and/or admission to the hospital is determined chiefly by the response to therapy with glucocorticoids and nebulized epinephrine. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Improvement </strong>– Most children with moderate croup have symptomatic improvement after treatment with nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> and glucocorticoids. If the child remains well-appearing at the end of the observation period, they can be discharged home provided other discharge criteria are met. (See <a class="local">'Discharge to home'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent or persistent symptoms</strong> – Children who have recurrent or persistent moderate to severe symptoms during the observation period should receive a second nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatment. Depending on resources, it is reasonable to observe the child in the ED for three to four hours after the second dose since in many cases, symptoms improve and the child can be discharged home. (See <a class="local">'Discharge to home'</a> below.)</p><p></p><p class="bulletIndent1">If resources do not permit extending the observation period in the ED or if symptoms recur or worsen after the second nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatment, the child should be hospitalized. Additional indications for hospital admission are summarized below. (See <a class="local">'Indications for hospital admission'</a> below.)</p><p></p><p class="bulletIndent1">For children with ongoing severe symptoms, nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> can be repeated every 15 to 20 minutes, if necessary, while arranging for admission to the pediatric intensive care unit (PICU). The administration of three or more doses within a two- to three-hour time period should prompt initiation of close cardiac monitoring if this is not already underway. (See <a class="local">'Monitoring'</a> below.)</p><p></p><p class="headingAnchor" id="H94690"><span class="h3">Discharge to home</span><span class="headingEndMark"> — </span>Patients who have a good response to initial treatment should be observed for three to four hours after pharmacologic intervention  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>) [<a href="#rid8">8-11</a>]. Croup symptoms usually improve within 30 minutes of administration of nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> but may recur as the effects of epinephrine wear off (usually by two hours) [<a href="#rid12">12,13</a>].</p><p>Children who remain well-appearing after three to four hours of observation (after either the first or second racemic <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatment) may be discharged home if they meet the following criteria [<a href="#rid8">8-11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No stridor at rest</p><p class="bulletIndent1"><span class="glyph">●</span>Normal pulse oximetry</p><p class="bulletIndent1"><span class="glyph">●</span>Good air exchange</p><p class="bulletIndent1"><span class="glyph">●</span>Normal color</p><p class="bulletIndent1"><span class="glyph">●</span>Normal level of consciousness</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstrated ability to tolerate fluids by mouth</p><p class="bulletIndent1"><span class="glyph">●</span>Caregivers understand the indications for return to care and would be able to return if necessary</p><p></p><p>Before discharge, follow-up with the primary care provider should be arranged within the next 24 hours. Instructions regarding home treatment should be provided. (See <a class="local">'Home treatment'</a> above.)</p><p>Approximately 3 to 5 percent of children well enough for discharge from the ED after receiving glucocorticoids and nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatments are expected to return for care [<a href="#rid14">14-16</a>]. Recurrence of symptoms within 24 hours is unlikely in those who have minimal symptoms at the time of discharge. (See <a class="local">'Recurrent symptoms'</a> below.)</p><p class="headingAnchor" id="H94978"><span class="h3">Indications for hospital admission</span></p><p>Indications for inpatient admission include [<a href="#rid2">2,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe croup with poor air entry, altered consciousness, or impending respiratory failure</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate/severe croup symptoms that recur or persist after initial treatment (consisting of glucocorticoids and one to two nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatments)</p><p class="bulletIndent1"><span class="glyph">●</span>"Toxic" appearance or clinical picture suggesting potential serious secondary bacterial infection</p><p class="bulletIndent1"><span class="glyph">●</span>Need for supplemental oxygen</p><p class="bulletIndent1"><span class="glyph">●</span>Severe dehydration</p><p></p><p>Additional factors that influence the decision regarding admission include [<a href="#rid2">2,17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Young age, particularly &lt;6 months</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent visits to the ED within 24 hours</p><p class="bulletIndent1"><span class="glyph">●</span>Ability of the parents/caregivers to comprehend the instructions regarding recognition of features that indicate the need to return for care</p><p class="bulletIndent1"><span class="glyph">●</span>Ability of the parents/caregivers to return for care (eg, distance from home to care site, weather/travel conditions)</p><p></p><p>Admission to the PICU is warranted if any of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory failure requiring endotracheal intubation</p><p class="bulletIndent1"><span class="glyph">●</span>Persistent severe symptoms requiring frequent nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> dosing</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying conditions placing the child at high risk for progressive respiratory failure (eg, neuromuscular disease or bronchopulmonary dysplasia)</p><p></p><p>Approximately 5 to 10 percent of children with croup presenting to the ED require hospitalization; only 1 percent require admission to the PICU [<a href="#rid14">14,15,18-20</a>]. Children who are admitted typically have a brief inpatient stay, and most do not require further nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatments or airway interventions [<a href="#rid18">18,20-22</a>].</p><p class="headingAnchor" id="H73608135"><span class="h2">Inpatient management</span><span class="headingEndMark"> — </span>Children admitted to the hospital for management of croup should receive close respiratory monitoring and supportive care.</p><p class="headingAnchor" id="H11"><span class="h3">Supportive care</span><span class="headingEndMark"> — </span>Supportive care for children hospitalized with moderate to severe croup includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluids</strong> – Administration of IV fluids may be necessary in some children. Fever and tachypnea may increase fluid requirements, and respiratory difficulty may prevent the child from achieving adequate oral intake. (See  <a class="medical medical_review" href="/z/d/html/6122.html" rel="external">"Maintenance intravenous fluid therapy in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever control</strong> – High fever can contribute to tachypnea and respiratory distress in children with croup, and treatment with antipyretics can improve work of breathing and insensible fluid losses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comfort</strong> – Care must be taken to avoid provoking agitation or anxiety in children with moderate to severe croup as this can worsen the degree of respiratory distress and airway obstruction. Children with severe croup should be approached cautiously, and unnecessary invasive interventions should be avoided. The parent or caregiver should be encouraged to hold and comfort the child and to assist in care. The use of sedatives or anxiolytics to reduce agitation is discouraged as this may cause respiratory depression.</p><p></p><p class="headingAnchor" id="H91700"><span class="h3">Respiratory care</span><span class="headingEndMark"> — </span>Respiratory support for children hospitalized with croup may include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nebulized </strong><a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> – Repeated doses of nebulized epinephrine may be warranted for children with moderate to severe distress; however, many children admitted for management of croup will not require subsequent epinephrine treatments [<a href="#rid20">20,23-25</a>]. One study of 628 hospitalizations for croup found that only approximately 20 percent required additional nebulized epinephrine during the inpatient stay [<a href="#rid20">20</a>]. Nebulized epinephrine can be repeated every 15 to 20 minutes. However, children who require frequent doses of epinephrine (eg, more frequently than every one to two hours) should be admitted/transferred to an ICU for close cardiopulmonary monitoring. (See <a class="local">'Monitoring'</a> below and <a class="local">'Nebulized epinephrine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental oxygen</strong> – Oxygen should be administered to children who are hypoxemic (oxygen saturation of &lt;92 percent in room air). (See  <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">"Continuous oxygen delivery systems for the acute care of infants, children, and adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mist</strong> – Humidified air is frequently used in the treatment of croup, although studies evaluating its efficacy are inconsistent [<a href="#rid26">26</a>]. If there is a benefit, it is likely marginal at best. Nevertheless, mist therapy may provide a sense of comfort and reassurance to both the child and parents/caregivers. However, if the child is instead agitated by the mist, it should be discontinued. (See <a class="local">'Mist therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-flow nasal cannula (HFNC) and noninvasive ventilation (NIV)</strong> – For children with ongoing severe tachypnea and work of breathing despite treatment with nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> and <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>, additional respiratory support can be provided with HFNC or other NIV modality (eg, continuous positive airway pressure [CPAP]). HFNC is the modality most commonly used, though there are limited data to support its use in this setting [<a href="#rid27">27</a>]. Additional details regarding HFNC and NIV are provided separately. (See  <a class="medical medical_review" href="/z/d/html/122550.html" rel="external">"High-flow nasal cannula oxygen therapy in children"</a> and  <a class="medical medical_review" href="/z/d/html/100358.html" rel="external">"Noninvasive ventilation for acute and impending respiratory failure in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heliox</strong> – Heliox is a mixture of helium (70 to 80 percent) and oxygen (20 to 30 percent). Heliox may decrease the work of breathing in children with severe croup by reducing turbulent airflow [<a href="#rid28">28</a>]. While heliox is not a routine intervention for children with croup, it is a reasonable intervention for children with severe respiratory distress that persists despite other interventions (eg, nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, glucocorticoids, and HFNC/NIV). In this setting, heliox can be used as a temporizing measure to prevent the need for intubation while waiting for glucocorticoids to decrease airway edema. A limitation of heliox use is the low fractional concentration of inspired oxygen (FiO<sub>2</sub>) in the gas mixture, which may not be adequate for children with hypoxia. However, hypoxia is relatively rare in children with isolated croup. (See <a class="local">'Heliox'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intubation</strong> – The need for intubation should be anticipated in children with progressive respiratory failure so that the procedure can be performed in a controlled setting, if possible. Intubation can be challenging due to the narrowed subglottic airway and should be performed with the assistance of experts in airway management (eg, an anesthesiologist or otolaryngologist) when possible. Neuromuscular blocking agents should be avoided unless the ability to provide bag-mask ventilation has been demonstrated. An endotracheal tube that is 0.5 to 1 mm smaller than would typically be used should be placed. (See <a class="local">'Croup severity score'</a> above and  <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">"Technique of emergency endotracheal intubation in children", section on 'Endotracheal tube'</a>.)</p><p></p><p class="bulletIndent1">Endotracheal intubation is rarely required for management of croup (&lt;3 percent of hospitalized patients in two large retrospective studies) [<a href="#rid18">18,19</a>]. In a retrospective series of 77 children with severe croup requiring intubation, the median duration of mechanical ventilation was 60 hours and 6.5 percent of patients required reintubation after the first attempt at extubation [<a href="#rid29">29</a>]. Of note, the endotracheal cuff leak (which is commonly used to assess risk of postextubation stridor) poorly predicted extubation failure in this study. One-half of the patients in this series were diagnosed with bacterial coinfection or superinfection. (See  <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">"Extubation management in the adult intensive care unit", section on 'Cuff leak'</a>.)</p><p></p><p class="headingAnchor" id="H91602"><span class="h3">Repeated glucocorticoid dosing</span><span class="headingEndMark"> — </span>Repeat doses of glucocorticoids are <strong>not</strong> routinely necessary but may be reasonable for the occasional child who has persistent symptoms [<a href="#rid30">30</a>]. The risk of adverse effects from glucocorticoids increases with repeat dosing. (See <a class="local">'Glucocorticoids'</a> below.)</p><p>Moderate to severe symptoms that persist for more than a few days should prompt investigation for other causes of airway obstruction. (See <a class="local">'Atypical course'</a> below and  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Monitoring should include close observation of mental status and respiratory status, including findings such as stridor, hypoxia, retractions, and poor air entry. Pulse oximetry monitoring is useful to detect hypoxia; however, it is not a sensitive tool for assessing the severity of croup [<a href="#rid17">17</a>]. Children who require ongoing <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatments more frequently than every one to two hours should have continuous cardiac monitoring, though adverse cardiac effects are rare.</p><p class="headingAnchor" id="H21"><span class="h3">Infection control</span><span class="headingEndMark"> — </span>Children who are admitted to the hospital with croup are typically managed initially with contact and droplet precautions (ie, gown and gloves, respiratory mask within three feet) if the viral etiology is unknown. If a specific viral pathogen is identified, precautions should be adjusted accordingly. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H22"><span class="h3">Discharge criteria</span><span class="headingEndMark"> — </span>Children who require hospital admission may be discharged when they meet the following criteria:</p><p class="bulletIndent1"><span class="glyph">●</span>No stridor at rest</p><p class="bulletIndent1"><span class="glyph">●</span>Normal pulse oximetry in room air</p><p class="bulletIndent1"><span class="glyph">●</span>Good air exchange</p><p class="bulletIndent1"><span class="glyph">●</span>Normal color</p><p class="bulletIndent1"><span class="glyph">●</span>Normal level of consciousness</p><p class="bulletIndent1"><span class="glyph">●</span>Demonstrated ability to tolerate fluids by mouth</p><p></p><p>Rebound symptoms are fairly common, particularly in children with severe croup. Thus, patients should be monitored for several hours to ensure they consistently meet these criteria. In one study of 275 children with croup admitted to the PICU, 37 percent developed rebound symptoms after initially meeting hospital discharge criteria [<a href="#rid31">31</a>]. The median time to occurrence of rebound symptoms was 13 hours. In another study of &gt;6000 patients hospitalized for croup, 3 percent were readmitted for croup within 30 days after discharge [<a href="#rid18">18</a>]. (See <a class="local">'Recurrent symptoms'</a> below.)</p><p class="headingAnchor" id="H96291"><span class="h3">Atypical course</span><span class="headingEndMark"> — </span>Children admitted for croup typically remain in the hospital for &lt;36 hours [<a href="#rid18">18,23</a>]. The child who does not show improvement as expected (over the course of one to two days) may have an underlying airway abnormality or may be developing a complication of croup. Further evaluation with radiographs of the soft tissues of the neck or consultation with otolaryngology may be warranted. A biphasic illness with poor response to nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> in conjunction with high fever and toxic appearance should prompt consideration of bacterial tracheitis  (<a class="graphic graphic_picture graphicRef55364" href="/z/d/graphic/55364.html" rel="external">picture 1</a>) [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6034.html" rel="external">"Bacterial tracheitis in children: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H137077982"><span class="h1">SPECIFIC THERAPIES FOR CROUP</span></p><p class="headingAnchor" id="H2413432114"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids have been shown to improve croup scores, reduce the need for <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, decrease length of stay in the emergency department (ED) or hospital, and reduce unscheduled medical visits [<a href="#rid3">3,4,32-34</a>]. Among the available agents, we suggest <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> for most children because it is the agent most extensively studied and it has a longer duration of action compared with other agents. Oral <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> is a reasonable alternative for children with mild croup. Nebulized <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> is an alternative option for children who are vomiting and who lack intravenous (IV) access.</p><p>The anti-inflammatory actions of glucocorticoids are thought to decrease edema in the laryngeal mucosa of children with croup. Improvement is usually evident within two to six hours of administration but seldom is dramatic [<a href="#rid3">3,35</a>].</p><p class="headingAnchor" id="H3246435298"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Glucocorticoids have been shown to be effective in croup of all levels of severity [<a href="#rid3">3,33</a>]. <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> (oral or intramuscular [IM]), <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a>, and <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> (inhaled) are the agents used in the majority of studies. In a meta-analysis of 10 trials (1679 children), glucocorticoids reduced the rate of return visits and hospital admission or readmission compared with placebo (11 versus 20 percent; risk ratio [RR] 0.52, 95% CI 0.36-0.75) [<a href="#rid3">3</a>]. Glucocorticoids also reduced croup symptom scores at 2, 6, 12, and 24 hours and reduced hospital length of stay by approximately 15 hours (95% CI 6-24 hours). There was no apparent difference in need for intubation between the glucocorticoid group and placebo group; however, there were very few events in either group.</p><p>The efficacy of glucocorticoids may differ depending on the specific agent and dose used, as discussed below. (See <a class="local">'Agents'</a> below.)</p><p class="headingAnchor" id="H2025279150"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Side effects associated with short-term glucocorticoid therapy may include hyperglycemia and behavioral changes; severe adverse effects are uncommon [<a href="#rid3">3,36-39</a>]. In clinical trials evaluating a <strong>single</strong> dose of glucocorticoids in croup, few serious adverse effects were reported; however, most of these studies were too small to sufficiently evaluate rare (&lt;1 percent) adverse effects [<a href="#rid3">3,36,37,40,41</a>].</p><p>The primary concern is potential risk of progressive viral infection or secondary bacterial infection, which have been reported in patients who received glucocorticoid treatment over several days [<a href="#rid40">40</a>], or received nebulized <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> and had neutropenia [<a href="#rid42">42</a>]. These complications have not been described in children who have received single doses of oral, IM, or IV glucocorticoids for croup. In placebo-controlled clinical trials, rates of secondary bacterial infection were low and similar in patients treated with steroids compared with placebo [<a href="#rid3">3</a>].</p><p>Administration of glucocorticoids may mask the presentation of steroid-responsive upper airway lesions, such as hemangiomas, which also can present with stridor, particularly during a viral upper respiratory tract infection [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p class="headingAnchor" id="H1196663316"><span class="h3">Agents</span><span class="headingEndMark"> — </span>Glucocorticoid agents that have been used for croup include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dexamethasone</strong> – <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> is our preferred glucocorticoid agent for most children with croup. It is the agent most extensively studied in this setting [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Route</strong> – <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> can be given IM, IV, or orally and should generally be administered via the least invasive route possible (orally if oral intake is tolerated, IV if IV access has been established, or intramuscular (IM) if oral intake is not tolerated and IV access has not been established). The oral liquid preparation of dexamethasone (1 mg per mL) has a foul taste. The IV preparation is more concentrated (4 mg per mL) and can be given orally mixed with syrup [<a href="#rid2">2,5</a>]. Alternatively, oral tablets can be crushed and mixed with syrup or pureed food.</p><p></p><p class="bulletIndent2">Based on the available evidence, there do not appear to be clinically significant differences in croup outcomes between IM and orally administered <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> [<a href="#rid3">3</a>]. Nebulized dexamethasone appears to be less effective than oral dexamethasone in reducing the need for additional treatments and preventing return visits [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose</strong> – The optimal dose of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> in children with croup is uncertain. In clinical trials, doses ranging from 0.15 to 0.6 mg/kg have been shown to be effective [<a href="#rid3">3</a>]. The maximum dose of dexamethasone used in these trials ranged from 10 mg to 20 mg, with most using 16 mg. For children with moderate to severe croup (ie, Westley croup score of ≥3  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>)), we suggest a single dose of 0.6 mg/kg (maximum 16 mg) [<a href="#rid45">45</a>]. Dexamethasone at this dose has proven efficacy in croup, as demonstrated in numerous clinical trials, including several high-quality placebo-controlled trials [<a href="#rid3">3,4,6,44</a>]. Based on these data, we also suggest a dose of 0.6 mg/kg (maximum 16 mg) for children with mild croup (ie, Westley croup score of ≤2  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>)); however, limited data suggest that lower doses (0.15 mg/kg to 0.4 mg/kg) may be equally effective in patients with mild croup [<a href="#rid3">3,46-49</a>]. Nonpharmacologic management is another reasonable alternative for patients with mild croup. (See <a class="local">'Mild croup'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Comparison with other agents</strong> – <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> has comparable or superior efficacy for treatment of croup compared with other glucocorticoids that have been evaluated [<a href="#rid3">3,50</a>]. In a meta-analysis of five trials (374 children) directly comparing dexamethasone with inhaled <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a>, dexamethasone achieved greater improvement in croup scores at 6 and 12 hours; however, rates of return visits or hospital admission or readmission were not appreciably different [<a href="#rid3">3</a>]. Studies comparing dexamethasone and <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> are discussed in the following section. Data comparing dexamethasone with other agents (eg, <a class="drug drug_pediatric" data-topicid="12996" href="/z/d/drug information/12996.html" rel="external">beclomethasone</a>, <a class="drug drug_pediatric" data-topicid="13046" href="/z/d/drug information/13046.html" rel="external">betamethasone</a>, <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">fluticasone</a>) are limited to single small clinical trials, and thus it is difficult to draw firm conclusions [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisolone</strong> – For children with mild croup who are managed as outpatients, oral <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> (single dose of 1 mg/kg) is an alternative to oral <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> [<a href="#rid50">50,51</a>]. The advantage of prednisolone is that it is more palatable than the oral liquid preparation of dexamethasone and may be easier for young children to take. In addition, prednisolone is widely available in most outpatient settings, whereas dexamethasone may not be as available.</p><p></p><p class="bulletIndent1">Based on the available data, <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> appears to be effective in improving croup symptoms in mildly affected patients; however, there may be an increased risk of symptom recurrence with prednisolone compared with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> [<a href="#rid3">3,50</a>].</p><p></p><p class="bulletIndent1">In a meta-analysis of four trials (1537 patients), the rate of return visits for recurrent symptoms was lower with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> compared with <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> (17 versus 21 percent), but the finding was not statistically significant; (RR 0.55, 95% CI 0.28-1.11) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Budesonide</strong> – Nebulized <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> is not routinely used in croup because it is more expensive and more difficult to administer than IM or oral <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>; however, it may provide an alternative to IM or IV dexamethasone for children with vomiting or severe respiratory distress in whom IV access cannot be readily obtained [<a href="#rid45">45</a>]. In children with severe respiratory distress, a single dose of budesonide may be mixed with <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> and administered simultaneously. In clinical trials, nebulized budesonide appears to have similar efficacy compared with IM or oral dexamethasone [<a href="#rid3">3,5,52-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beclomethasone</strong> – Inhaled <a class="drug drug_pediatric" data-topicid="12996" href="/z/d/drug information/12996.html" rel="external">beclomethasone</a> has been evaluated in a single small, randomized trial in 39 children with croup [<a href="#rid55">55</a>]. Improvements in croup scores and the rate of return visits was similar to that of children treated with IM <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a>. However, the small study size (39 patients) makes it difficult to draw firm conclusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Betamethasone</strong> – A pilot study compared the effectiveness of a single oral dose of <a class="drug drug_pediatric" data-topicid="13046" href="/z/d/drug information/13046.html" rel="external">betamethasone</a> (0.4 mg/kg) with a single dose of IM <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> (0.6 mg/kg) in 52 children with mild to moderate croup who were treated in the ED [<a href="#rid56">56</a>]. Despite randomization, mean baseline croup scores were higher in the dexamethasone group (3.6 versus 2). Croup scores declined significantly in both groups, and there were no differences between groups in mean croup scores four hours after treatment, rate of hospitalization, time to resolution of symptoms, need for additional treatment, or number of return visits to the ED.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluticasone</strong> – In a small trial in 17 children hospitalized for croup, inhaled <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">fluticasone</a> did not improve croup scores or reduce length of hospital stay compared with placebo [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prednisone</strong> – The use of <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> in the management of croup has not been evaluated in clinical trials. However, it has equivalent potency to <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> and, in theory, should have similar effects.</p><p></p><p class="headingAnchor" id="H1093975859"><span class="h2">Nebulized epinephrine</span><span class="headingEndMark"> — </span>Nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> is effective for reducing stridor and work of breathing in children with croup [<a href="#rid1">1,58,59</a>]. It is used for acute symptom relief in patients with moderate to severe croup. Epinephrine has rapid onset and works by decreasing airway edema, which helps relieve airway obstruction [<a href="#rid60">60</a>]. Even a small relief in airway swelling can result in considerable short-term clinical improvement. However, epinephrine does not alter the natural history of croup.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Racemic versus L-epinephrine</strong> – Racemic <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> (which is a 1:1 mixture of the D- and L-isomers) and L-epinephrine appear to have similar efficacy and a similar side effect profile [<a href="#rid12">12</a>]. Thus, either form of epinephrine is acceptable to use for treatment of croup. Racemic epinephrine is not available in some areas outside of the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – Dosing and administration of nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Racemic <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> is administered as 0.05 mL/kg per dose (maximum of 0.5 mL) of a 2.25% solution diluted to 3 mL total volume with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>. It is given via nebulizer over 15 minutes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>L-epinephrine is administered as 0.5 mL/kg per dose (maximum of 5 mL) of a 1 mg/mL solution [<a href="#rid12">12</a>]. It is given via nebulizer over 15 minutes.</p><p></p><p class="bulletIndent1">Nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> treatments may be repeated every 15 to 20 minutes if warranted by the degree of symptoms. However, children who require frequent doses of epinephrine (eg, more frequently than every one to two hours) should be admitted/transferred to an intensive care unit (ICU) for close cardiopulmonary monitoring. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In a meta-analysis of eight placebo-controlled trials (225 patients), nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> improved 30-minute posttreatment croup scores in children with moderate to severe croup [<a href="#rid58">58</a>]. The mean reduction in croup score from baseline in the individual trials ranged from 2.2 to 3.6 (compared with approximately 1 in the placebo group). However, the benefit dissipated by two hours post-treatment [<a href="#rid1">1,61</a>].</p><p></p><p class="bulletIndent1">The method of administration varied in the trials, with some using simple nebulization and others using intermittent positive pressure breaths [<a href="#rid1">1,58,61,62</a>]. A study comparing these two methods found them to be similarly effective [<a href="#rid63">63</a>]. Thus, simple nebulization is the method used most commonly in clinical practice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects and cautions</strong> – Serious adverse effects from nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> are rare. Children who require ongoing epinephrine treatments more frequently than every one to two hours should be admitted/transferred to an ICU for close cardiopulmonary monitoring. Adverse cardiac effects (eg, arrhythmia, myocardial ischemia) from nebulized epinephrine have rarely been reported [<a href="#rid64">64</a>]. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1">In addition to the potential for adverse cardiac effects, it is important for clinicians to be aware that since the clinical effects are short-lived (typically lasting for no more than two hours), some children may experience a "rebound phenomenon," wherein croup symptoms worsen or recur as the effects of <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> wear off. Thus, children who receive even a single dose of nebulized epinephrine should be observed in the ED or hospital setting for at least three to four hours after administration to ensure that symptoms do not recur. (See <a class="local">'Discharge to home'</a> above.)</p><p></p><p class="headingAnchor" id="H824861782"><span class="h2">Heliox</span><span class="headingEndMark"> — </span>Helium is an inert, nontoxic, low-density gas. Heliox is a mixture of helium (70 to 80 percent) and oxygen (20 to 30 percent). Because of its lower density, heliox flows through narrow airways with less turbulence and resistance than oxygen-nitrogen mixtures. (See  <a class="medical medical_review" href="/z/d/html/541.html" rel="external">"Physiology and clinical use of heliox"</a>.)</p><p>Heliox is not a routine intervention for children with croup, but it may decrease the work of breathing in children with severe respiratory distress and can be used as a temporizing measure to prevent the need for intubation while waiting for glucocorticoids to decrease airway edema [<a href="#rid65">65</a>].</p><p>In clinical trials involving children with mild to moderate croup, heliox has not definitively been shown to be more effective than humidified oxygen for reducing croup symptoms [<a href="#rid28">28,66-68</a>]. A 2018 systematic review identified only three methodologically limited clinical trials (91 patients) evaluating heliox in children with croup [<a href="#rid28">28</a>]. In the largest trial (n = 47), heliox modestly improved croup scores at one hour after initiating treatment (mean difference -1.1, 95% CI -1.96 to -0.24), but the difference at two hours was no longer statistically significant (mean difference -0.7, 95% CI -1.56 to 0.16) [<a href="#rid68">68</a>]. No conclusion could be reached as to whether heliox reduced the need for hospitalization since few patients in either treatment group required hospitalization (one in the heliox group, two in the control group).</p><p class="headingAnchor" id="H2928669774"><span class="h2">Mist therapy</span><span class="headingEndMark"> — </span>Humidified air is frequently used in the treatment of croup, although studies supporting its efficacy in reducing symptoms are limited [<a href="#rid26">26</a>]. Two randomized trials (one comparing mist versus no mist and the other comparing no mist, low humidity, and 100 percent humidity) among children brought to an ED for croup found that the changes in croup scores from baseline were similar in children treated with and without mist [<a href="#rid69">69,70</a>].</p><p>Although humidified air does not reduce subglottic edema, it may provide other benefits. Inhalation of moist air, relative to dry air, may decrease drying of inflamed mucosal surfaces and reduce inspissation of secretions [<a href="#rid71">71</a>]. In addition, a mist source may provide a sense of comfort and reassurance to both the child and parents/caregivers [<a href="#rid72">72-74</a>]. In medical settings, mist therapy may be provided by blow-by or <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> nebulization treatments. Croup tents should be avoided since they can aggravate a child's anxiety and make vital signs and other visual assessments of the child more difficult. Some guidelines recommend against the use of mist therapy for children who are hospitalized with croup [<a href="#rid45">45</a>]. Certainly, if the child is agitated by the provision of mist, mist therapy should be discontinued.</p><p class="headingAnchor" id="H3355450583"><span class="h2">Therapies not routinely recommended</span><span class="headingEndMark"> — </span>Antibiotics, antitussives, decongestants, and sedatives generally do <strong>not</strong> play a role in management of croup.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Antibiotics have no role in the routine management of uncomplicated croup, since most cases are caused by viruses [<a href="#rid36">36</a>]. Antibiotics should be used only to treat specific bacterial complications, such as tracheitis. (See  <a class="medical medical_review" href="/z/d/html/6044.html" rel="external">"Bacterial tracheitis in children: Treatment and prevention", section on 'Antibiotic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antitussives and decongestants</strong> – Over-the-counter antitussive and decongestant medications are of unproven benefit for croup and should generally be avoided in children &lt;2 years due to risk of adverse effects [<a href="#rid45">45,75</a>]. Opioid-containing cough and cold medicines (eg, <a class="drug drug_pediatric" data-topicid="13178" href="/z/d/drug information/13178.html" rel="external">codeine</a>) should be avoided in all children [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sedatives</strong> – The use of sedative agents in effort to improve airway obstruction by relieving anxiety and apprehension is <strong>not</strong> recommended. Sedatives may treat the symptom of agitation while masking the underlying causes of air hunger and hypoxia. They also may decrease respiratory effort (and therefore croup scores), without improving ventilation [<a href="#rid36">36,77</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Any patient who was admitted to the hospital, received nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, or had a prolonged outpatient visit (clinic/office, urgent care, or emergence department) should have follow-up scheduled with the primary care provider within 24 hours or as soon as can be arranged. Although some children may continue to have mild to moderate symptoms at the time of follow-up, the available evidence does not support routine use of glucocorticoid therapy beyond 24 hours.</p><p>Follow-up should continue until the child's symptoms have begun to resolve. The child whose symptoms do not resolve over the course of approximately seven days may have an underlying airway abnormality or may be developing a complication of croup. (See <a class="local">'Atypical course'</a> above.)</p><p class="headingAnchor" id="H24"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Symptoms of croup resolve in most children within three days but may persist for up to one week [<a href="#rid18">18,40,78</a>]. Approximately 8 to 15 percent of children with croup require hospital admission [<a href="#rid14">14,36</a>], and, among those, &lt;3 percent require intubation [<a href="#rid18">18,19</a>]. Mortality is rare, occurring in &lt;1 percent of intubated children [<a href="#rid18">18,79</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Complications</span><span class="headingEndMark"> — </span>Complications of croup are uncommon. Children with moderate to severe croup are at risk for respiratory failure. Other complications include postobstructive pulmonary edema, pneumothorax, and pneumomediastinum [<a href="#rid80">80,81</a>]. These complications can be anticipated and managed by intensive monitoring and intervention in the medical setting. Out-of-hospital cardiac arrest and death also have been reported [<a href="#rid82">82</a>].</p><p>Secondary bacterial infections may arise from croup. Bacterial tracheitis, bronchopneumonia, and pneumonia occur in a small number of patients [<a href="#rid40">40,83</a>]. In most instances, the child has been relatively stable or beginning to improve after several days of illness, but then suddenly worsens, with higher or recurrent fever, increased (and potentially productive) cough, and/or respiratory distress. (See  <a class="medical medical_review" href="/z/d/html/6034.html" rel="external">"Bacterial tracheitis in children: Clinical features and diagnosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/5986.html" rel="external">"Community-acquired pneumonia in children: Clinical features and diagnosis", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H96554549"><span class="h2">Recurrent symptoms</span><span class="headingEndMark"> — </span>Approximately 5 percent of children treated for croup in the outpatient setting have repeat visits for recurrent symptoms within seven days following discharge [<a href="#rid14">14,18</a>].</p><p>Children who have recurrent episodes of croup should be referred to an otolaryngologist to evaluate for underlying airway abnormalities (eg, laryngomalacia, subglottic stenosis, reflux changes, hemangioma). In the available cases series, airway abnormalities were identified in approximately 10 percent of children with recurrent croup referred to otolaryngologists and approximately 45 percent of those who underwent airway endoscopy [<a href="#rid84">84-91</a>]. Most airway abnormalities identified in these series were mild and did not require surgical intervention [<a href="#rid91">91</a>]. (See  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Recurrent croup'</a> and  <a class="medical medical_review" href="/z/d/html/6380.html" rel="external">"Assessment of stridor in children"</a>.)</p><p>Although an association between recurrent croup and gastroesophageal reflux has been reported, it is unclear if there is a causal relationship [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/z/d/html/5892.html" rel="external">"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents", section on 'Other conditions'</a>.)</p><p>Some children with recurrent croup follow a fairly typical pattern referred to as "spasmodic croup," which is characterized by intermittent episodes of exclusively nighttime symptoms with abrupt onset and cessation and relative wellness between episodes. This occurs most commonly in children with allergic conditions or family history of allergies. Spasmodic croup usually has a benign course and most children outgrow it by school age. (See  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Spasmodic croup'</a>.)</p><p class="headingAnchor" id="H4217596831"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112430.html" rel="external">"Society guideline links: Croup"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15390.html" rel="external">"Patient education: Croup (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/1201.html" rel="external">"Patient education: Croup in infants and children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severity assessment</strong> – Management of children with croup begins with an assessment of severity  (<a class="graphic graphic_table graphicRef100744" href="/z/d/graphic/100744.html" rel="external">table 1</a>) (<a class="calc calc_patient" href="/z/d/html/105432.html" rel="external">calculator 1</a>). This can be accomplished via telephone triage or by examining the child in the office or emergency department (ED) setting. If concerns arise on telephone triage (eg, stridor at rest, underlying airway abnormality, previous episodes of moderate to severe croup, underlying conditions that may predispose to respiratory failure, rapid progression of symptoms, inability to tolerate fluids, prolonged symptoms, or atypical course), the child should be seen in the office or ED  (<a class="graphic graphic_algorithm graphicRef141709" href="/z/d/graphic/141709.html" rel="external">algorithm 2</a>). (See <a class="local">'Severity assessment'</a> above and <a class="local">'Telephone triage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of mild croup</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Home treatment</strong> – Children with mild symptoms (ie, no stridor at rest and no respiratory distress) can be managed at home. Parents/caregivers should be instructed to provide supportive care (fever reduction and encourage fluids) and indications to seek medical attention. (See <a class="local">'Home treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Outpatient treatment</strong> – For children with mild croup who are seen in the office or ED setting, we suggest a single dose of <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> or <a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">prednisolone</a> rather than supportive care alone  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). In this setting, the appropriate dose of dexamethasone is 0.15 to 0.6 mg/kg (maximum 16 mg) given orally. Prednisolone is given orally at a dose of 1 mg/kg. Supportive care alone is a reasonable alternative. (See <a class="local">'Outpatient treatment'</a> above and <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of moderate to severe croup</strong> – Children with moderate croup (ie, stridor at rest with mild to moderate retractions) should be evaluated in the office or ED, and those with severe croup (stridor at rest with marked retractions and significant distress or agitation) should be evaluated in the ED  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>). In children with severe croup, agitation and crying may worsen airway obstruction. Parents/caregivers should be encouraged to hold and comfort the child to minimize agitation. (See <a class="local">'Moderate to severe croup'</a> above.)</p><p></p><p class="bulletIndent1">For children with moderate to severe croup, we recommend initial treatment with nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> and a single dose of glucocorticoid rather than either drug alone or supportive care only (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Initial treatment'</a> above and <a class="local">'Glucocorticoids'</a> above and <a class="local">'Nebulized epinephrine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dexamethasone</strong> – We suggest <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> rather than other glucocorticoids for treatment of moderate to severe croup (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer dexamethasone because it is long-acting and is the agent most extensively studied for treatment of croup. Dexamethasone is given at a dose of 0.6 mg/kg (maximum of 16 mg) orally or via intravenous (IV) or intramuscular (IM) injection (oral is preferred, if possible). (See <a class="local">'Initial treatment'</a> above and <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nebulized </strong><strong>epinephrine</strong> – Dosing of nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> depends on the product used: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Racemic <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> is administered as 0.05 mL/kg per dose (maximum of 0.5 mL) of a 2.25% solution diluted to 3 mL total volume with normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a>. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>L-epinephrine is administered as 0.5 mL/kg per dose (maximum of 5 mL) of a 1 mg/mL solution. </p><p></p><p class="bulletIndent2">In both cases, it is given via nebulizer over 15 minutes. Use of either product is acceptable and is determined by availability and institutional protocol. Nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> can be repeated every 15 to 20 minutes. The administration of three or more doses within a two- to three-hour time period should prompt initiation of close cardiac monitoring if this is not already underway. (See <a class="local">'Initial treatment'</a> above and <a class="local">'Nebulized epinephrine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Supportive care</strong> – Supportive care includes antipyretics, fluids (orally if the child is able or IV if the respiratory status does not permit oral intake), and oxygen or humidified air as needed. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Observation and disposition</strong> – Children should be observed for three to four hours after receiving nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>. Those who improve may be discharged home. Children with persistent or worsening symptoms during the observation period after one to two doses of nebulized epinephrine should be admitted to the hospital  (<a class="graphic graphic_algorithm graphicRef100747" href="/z/d/graphic/100747.html" rel="external">algorithm 1</a>). (See <a class="local">'Discharge to home'</a> above and <a class="local">'Indications for hospital admission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hospital management</strong> – Management of children hospitalized for croup includes (see <a class="local">'Inpatient management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing supportive care with provision of IV fluids and fever reduction as needed. (See <a class="local">'Supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monitoring for worsening respiratory distress. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repeated doses of nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a> if there is recurrence of moderate to severe croup symptoms (eg, stridor at rest). (See <a class="local">'Nebulized epinephrine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional respiratory care with administration of humidified air, oxygen, or advanced respiratory support, as indicated by hypoxemia and work of breathing. (See <a class="local">'Respiratory care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, we suggest <strong>not</strong> routinely using repeated doses of glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, repeat dosing is reasonable for the occasional child who has persistent symptoms. (See <a class="local">'Repeated glucocorticoid dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent or recurrent symptoms</strong> – Children who have moderate to severe symptoms that persist for more than a few days or recurring episodes of croup not associated with other manifestations of a viral illness (no fever and/or rhinorrhea) should undergo investigation for other causes of upper airway obstruction. (See <a class="local">'Atypical course'</a> above and <a class="local">'Recurrent symptoms'</a> above and  <a class="medical medical_review" href="/z/d/html/6002.html" rel="external">"Croup: Clinical features, evaluation, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Most children with croup recover uneventfully. Children who received nebulized <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">epinephrine</a>, had a prolonged outpatient visit (clinic/office, urgent care, or ED), or were admitted to the hospital should have follow-up scheduled with the primary care provider within 24 hours of discharge or as soon as follow-up can be arranged. (See <a class="local">'Follow-up'</a> above and <a class="local">'Outcome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Westley CR, Cotton EK, Brooks JG. Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study. Am J Dis Child 1978; 132:484.</a></li><li class="breakAll">Alberta Clinical Practice Guidelines Guideline Working Group. Guidelines for the diagnosis and management of croup. Available at: www.topalbertadoctors.org/download/252/croup_guideline.pdf (Accessed on March 13, 2015).</li><li><a class="nounderline abstract_t">Aregbesola A, Tam CM, Kothari A, et al. Glucocorticoids for croup in children. Cochrane Database Syst Rev 2023; 1:CD001955.</a></li><li><a class="nounderline abstract_t">Bjornson CL, Klassen TP, Williamson J, et al. A randomized trial of a single dose of oral dexamethasone for mild croup. N Engl J Med 2004; 351:1306.</a></li><li><a class="nounderline abstract_t">Klassen TP, Craig WR, Moher D, et al. Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial. JAMA 1998; 279:1629.</a></li><li><a class="nounderline abstract_t">Johnson DW, Jacobson S, Edney PC, et al. A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup. N Engl J Med 1998; 339:498.</a></li><li><a class="nounderline abstract_t">Clarke M, Allaire J. An evidence-based approach to the evaluation and treatment of croup in children. Pediatr Emerg Med Pract 2012; 9:1.</a></li><li><a class="nounderline abstract_t">Prendergast M, Jones JS, Hartman D. Racemic epinephrine in the treatment of laryngotracheitis: can we identify children for outpatient therapy? Am J Emerg Med 1994; 12:613.</a></li><li><a class="nounderline abstract_t">Ledwith CA, Shea LM, Mauro RD. Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup. Ann Emerg Med 1995; 25:331.</a></li><li><a class="nounderline abstract_t">Kunkel NC, Baker MD. Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup. Pediatr Emerg Care 1996; 12:156.</a></li><li><a class="nounderline abstract_t">Rizos JD, DiGravio BE, Sehl MJ, Tallon JM. The disposition of children with croup treated with racemic epinephrine and dexamethasone in the emergency department. J Emerg Med 1998; 16:535.</a></li><li><a class="nounderline abstract_t">Waisman Y, Klein BL, Boenning DA, et al. Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup). Pediatrics 1992; 89:302.</a></li><li><a class="nounderline abstract_t">Fitzgerald D, Mellis C, Johnson M, et al. Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup. Pediatrics 1996; 97:722.</a></li><li><a class="nounderline abstract_t">Rosychuk RJ, Klassen TP, Metes D, et al. Croup presentations to emergency departments in Alberta, Canada: a large population-based study. Pediatr Pulmonol 2010; 45:83.</a></li><li><a class="nounderline abstract_t">Hanna J, Brauer PR, Morse E, et al. Epidemiological analysis of croup in the emergency department using two national datasets. Int J Pediatr Otorhinolaryngol 2019; 126:109641.</a></li><li><a class="nounderline abstract_t">Hester G, Nickel AJ, Watson D, et al. Use of a Clinical Guideline and Orderset to Reduce Hospital Admissions for Croup. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Petrocheilou A, Tanou K, Kalampouka E, et al. Viral croup: diagnosis and a treatment algorithm. Pediatr Pulmonol 2014; 49:421.</a></li><li><a class="nounderline abstract_t">Tyler A, McLeod L, Beaty B, et al. Variation in Inpatient Croup Management and Outcomes. Pediatrics 2017.</a></li><li><a class="nounderline abstract_t">Dobrovoljac M, Geelhoed GC. 27 years of croup: an update highlighting the effectiveness of 0.15 mg/kg of dexamethasone. Emerg Med Australas 2009; 21:309.</a></li><li><a class="nounderline abstract_t">Asmundsson AS, Arms J, Kaila R, et al. Hospital Course of Croup After Emergency Department Management. Hosp Pediatr 2019; 9:326.</a></li><li><a class="nounderline abstract_t">Elder AE, Rao A. Management and outcomes of patients presenting to the emergency department with croup: Can we identify which patients can safely be discharged from the emergency department? J Paediatr Child Health 2019; 55:1323.</a></li><li><a class="nounderline abstract_t">Hancock WC, Scott M, Winer JC. Predictors of Inpatient Racemic Epinephrine Use in Patients Admitted With Croup. Hosp Pediatr 2023; 13:258.</a></li><li><a class="nounderline abstract_t">Narayanan S, Funkhouser E. Inpatient hospitalizations for croup. Hosp Pediatr 2014; 4:88.</a></li><li><a class="nounderline abstract_t">Chiang E, Afandi O, Lee SH, et al. Inpatient use of racemic epinephrine for children admitted with croup. World J Pediatr 2019; 15:586.</a></li><li><a class="nounderline abstract_t">Rudinsky SL, Sharieff GQ, Law W, Kanegaye JT. Inpatient Treatment after Multi-Dose Racemic Epinephrine for Croup in the Emergency Department. J Emerg Med 2015; 49:408.</a></li><li><a class="nounderline abstract_t">Moore M, Little P. Humidified air inhalation for treating croup. Cochrane Database Syst Rev 2006; :CD002870.</a></li><li><a class="nounderline abstract_t">Wing R, James C, Maranda LS, Armsby CC. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. Pediatr Emerg Care 2012; 28:1117.</a></li><li><a class="nounderline abstract_t">Moraa I, Sturman N, McGuire TM, van Driel ML. Heliox for croup in children. Cochrane Database Syst Rev 2018; 10:CD006822.</a></li><li><a class="nounderline abstract_t">Gelbart B, Parsons S, Sarpal A, et al. Intensive care management of children intubated for croup: a retrospective analysis. Anaesth Intensive Care 2016; 44:245.</a></li><li><a class="nounderline abstract_t">Tyler A, Bryan MA, Zhou C, et al. Variation in Dexamethasone Dosing and Use Outcomes for Inpatient Croup. Hosp Pediatr 2022; 12:22.</a></li><li><a class="nounderline abstract_t">Tyler A, Anderson L, Moss A, et al. Predictors of Symptom Rebound in Critically Ill Patients With Croup. Hosp Pediatr 2019; 9:447.</a></li><li><a class="nounderline abstract_t">Kairys SW, Olmstead EM, O'Connor GT. Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials. Pediatrics 1989; 83:683.</a></li><li><a class="nounderline abstract_t">Tibballs J, Shann FA, Landau LI. Placebo-controlled trial of prednisolone in children intubated for croup. Lancet 1992; 340:745.</a></li><li><a class="nounderline abstract_t">Gates A, Johnson DW, Klassen TP. Glucocorticoids for Croup in Children. JAMA Pediatr 2019; 173:595.</a></li><li><a class="nounderline abstract_t">Geelhoed GC, Macdonald WB. Oral and inhaled steroids in croup: a randomized, placebo-controlled trial. Pediatr Pulmonol 1995; 20:355.</a></li><li><a class="nounderline abstract_t">Johnson D. Croup. Clin Evid 2005; :310.</a></li><li><a class="nounderline abstract_t">Fernandes RM, Oleszczuk M, Woods CR, et al. The Cochrane Library and safety of systemic corticosteroids for acute respiratory conditions in children: an overview of reviews. Evid Based Child Health 2014; 9:733.</a></li><li><a class="nounderline abstract_t">Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc 2014; 89:817.</a></li><li><a class="nounderline abstract_t">Fernandes RM, Wingert A, Vandermeer B, et al. Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis. BMJ Open 2019; 9:e028511.</a></li><li class="breakAll">Cherry JD. Croup (laryngitis, laryngotracheitis, spasmodic croup, laryngotracheobronchitis, bacterial tracheitis, and laryngotracheobronchopneumonitis) and epiglottitis (supraglottitis). In: Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.241.</li><li><a class="nounderline abstract_t">Vernacchio L, Mitchell AA. Oral dexamethasone for mild croup. N Engl J Med 2004; 351:2768.</a></li><li><a class="nounderline abstract_t">Johnson DW, Schuh S, Koren G, Jaffee DM. Outpatient treatment of croup with nebulized dexamethasone. Arch Pediatr Adolesc Med 1996; 150:349.</a></li><li><a class="nounderline abstract_t">Kiff KM, Mok Q, Dunne J, Tasker RC. Steroids for intubated croup masking airway haemangioma. Arch Dis Child 1996; 74:66.</a></li><li><a class="nounderline abstract_t">Luria JW, Gonzalez-del-Rey JA, DiGiulio GA, et al. Effectiveness of oral or nebulized dexamethasone for children with mild croup. Arch Pediatr Adolesc Med 2001; 155:1340.</a></li><li class="breakAll">Alberta Clinical Practice Guideline WorkingGroup. Guideline for the diagnosis and management of croup. 2008. www.topalbertadoctors.org/download/252/croup_guideline.pdf (Accessed on October 31, 2013).</li><li><a class="nounderline abstract_t">Geelhoed GC, Turner J, Macdonald WB. Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial. BMJ 1996; 313:140.</a></li><li><a class="nounderline abstract_t">Geelhoed GC, Macdonald WB. Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol 1995; 20:362.</a></li><li><a class="nounderline abstract_t">Fifoot AA, Ting JY. Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial. Emerg Med Australas 2007; 19:51.</a></li><li><a class="nounderline abstract_t">Alshehr M, Almegamsi T, Hammdi A. Efficacy of a small dose of oral dexamethasone in croup. Biomed Res 2005; 16:65.</a></li><li><a class="nounderline abstract_t">Parker CM, Cooper MN. Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Garbutt JM, Conlon B, Sterkel R, et al. The comparative effectiveness of prednisolone and dexamethasone for children with croup: a community-based randomized trial. Clin Pediatr (Phila) 2013; 52:1014.</a></li><li><a class="nounderline abstract_t">Cetinkaya F, Tüfekçi BS, Kutluk G. A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup. Int J Pediatr Otorhinolaryngol 2004; 68:453.</a></li><li><a class="nounderline abstract_t">Geelhoed GC. Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup. Pediatr Emerg Care 2005; 21:359.</a></li><li><a class="nounderline abstract_t">Klassen TP, Watters LK, Feldman ME, et al. The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup. Pediatrics 1996; 97:463.</a></li><li><a class="nounderline abstract_t">Eboriadou M, Chryssanthopoulou D, Stamoulis P, et al. The effectiveness of local corticosteroids therapy in the management of mild to moderate viral croup. Minerva Pediatr 2010; 62:23.</a></li><li><a class="nounderline abstract_t">Amir L, Hubermann H, Halevi A, et al. Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup: a prospective, randomized trial. Pediatr Emerg Care 2006; 22:541.</a></li><li><a class="nounderline abstract_t">Roorda RJ, Walhof CM. Effects of inhaled fluticasone propionate administered with metered dose inhaler and spacer in mild to moderate croup: a negative preliminary report. Pediatr Pulmonol 1998; 25:114.</a></li><li><a class="nounderline abstract_t">Bjornson C, Russell K, Vandermeer B, et al. Nebulized epinephrine for croup in children. Cochrane Database Syst Rev 2013; :CD006619.</a></li><li><a class="nounderline abstract_t">Lee JH, Jung JY, Lee HJ, et al. Efficacy of low-dose nebulized epinephrine as treatment for croup: A randomized, placebo-controlled, double-blind trial. Am J Emerg Med 2019; 37:2171.</a></li><li><a class="nounderline abstract_t">Kaditis AG, Wald ER. Viral croup: current diagnosis and treatment. Pediatr Infect Dis J 1998; 17:827.</a></li><li><a class="nounderline abstract_t">Taussig LM, Castro O, Beaudry PH, et al. Treatment of laryngotracheobronchitis (croup). Use of intermittent positive-pressure breathing and racemic epinephrine. Am J Dis Child 1975; 129:790.</a></li><li><a class="nounderline abstract_t">Kristjánsson S, Berg-Kelly K, Winsö E. Inhalation of racemic adrenaline in the treatment of mild and moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation of treatment effects. Acta Paediatr 1994; 83:1156.</a></li><li><a class="nounderline abstract_t">Fogel JM, Berg IJ, Gerber MA, Sherter CB. Racemic epinephrine in the treatment of croup: nebulization alone versus nebulization with intermittent positive pressure breathing. J Pediatr 1982; 101:1028.</a></li><li><a class="nounderline abstract_t">Butte MJ, Nguyen BX, Hutchison TJ, et al. Pediatric myocardial infarction after racemic epinephrine administration. Pediatrics 1999; 104:e9.</a></li><li><a class="nounderline abstract_t">Duncan PG. Efficacy of helium--oxygen mixtures in the management of severe viral and post-intubation croup. Can Anaesth Soc J 1979; 26:206.</a></li><li><a class="nounderline abstract_t">Terregino CA, Nairn SJ, Chansky ME, Kass JE. The effect of heliox on croup: a pilot study. Acad Emerg Med 1998; 5:1130.</a></li><li><a class="nounderline abstract_t">Weber JE, Chudnofsky CR, Younger JG, et al. A randomized comparison of helium-oxygen mixture (Heliox) and racemic epinephrine for the treatment of moderate to severe croup. Pediatrics 2001; 107:E96.</a></li><li><a class="nounderline abstract_t">Pardillo MR, Citores AP, Navarro CM, et al. Heliox as mild treatment for croup [Heliox como tratamiento del crup moderado]. Acta Pediatr Esp 2009; 67:432.</a></li><li><a class="nounderline abstract_t">Neto GM, Kentab O, Klassen TP, Osmond MH. A randomized controlled trial of mist in the acute treatment of moderate croup. Acad Emerg Med 2002; 9:873.</a></li><li><a class="nounderline abstract_t">Scolnik D, Coates AL, Stephens D, et al. Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial. JAMA 2006; 295:1274.</a></li><li><a class="nounderline abstract_t">Dulfano MJ, Adler K, Wooten O. Physical properties of sputum. IV. Effects of 100 per cent humidity and water mist. Am Rev Respir Dis 1973; 107:130.</a></li><li><a class="nounderline abstract_t">Parks CR. Mist therapy: rationale and practice. J Pediatr 1970; 76:305.</a></li><li><a class="nounderline abstract_t">Henry R. Moist air in the treatment of laryngotracheitis. Arch Dis Child 1983; 58:577.</a></li><li><a class="nounderline abstract_t">Sasaki CT, Suzuki M. The respiratory mechanism of aerosol inhalation in the treatment of partial airway obstruction. Pediatrics 1977; 59:689.</a></li><li class="breakAll">FDA: Use Caution When Giving Cough and Cold Products to Kids. Available at: https://www.fda.gov/Drugs/ResourcesForYou/SpecialFeatures/ucm263948.htm (Accessed on January 12, 2018).</li><li class="breakAll">FDA Drug Safety Communication: FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older. Availabe at: https://www.fda.gov/Drugs/DrugSafety/ucm590435.htm (Accessed on January 12, 2018).</li><li><a class="nounderline abstract_t">Fanconi S, Burger R, Maurer H, et al. Transcutaneous carbon dioxide pressure for monitoring patients with severe croup. J Pediatr 1990; 117:701.</a></li><li><a class="nounderline abstract_t">Thompson M, Vodicka TA, Blair PS, et al. Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013; 347:f7027.</a></li><li><a class="nounderline abstract_t">McEniery J, Gillis J, Kilham H, Benjamin B. Review of intubation in severe laryngotracheobronchitis. Pediatrics 1991; 87:847.</a></li><li><a class="nounderline abstract_t">Garyfallou GT, Costalas SK, Murphy CJ. Acute pulmonary edema in a child with spasmodic croup. Am J Emerg Med 1997; 15:211.</a></li><li><a class="nounderline abstract_t">Lin HW, Kakarala K, Ostrower ST, Leonard DS. Laryngotracheobronchitis complicated by spontaneous pneumomediastinum. Int J Pediatr Otorhinolaryngol 2010; 74:221.</a></li><li><a class="nounderline abstract_t">Fisher JD. Out-of-hospital cardiopulmonary arrest in children with croup. Pediatr Emerg Care 2004; 20:35.</a></li><li><a class="nounderline abstract_t">Sofer S, Dagan R, Tal A. The need for intubation in serious upper respiratory tract infection in pediatric patients (a retrospective study). Infection 1991; 19:131.</a></li><li><a class="nounderline abstract_t">Cooper T, Kuruvilla G, Persad R, El-Hakim H. Atypical croup: association with airway lesions, atopy, and esophagitis. Otolaryngol Head Neck Surg 2012; 147:209.</a></li><li><a class="nounderline abstract_t">Duval M, Tarasidis G, Grimmer JF, et al. Role of operative airway evaluation in children with recurrent croup: a retrospective cohort study. Clin Otolaryngol 2015; 40:227.</a></li><li><a class="nounderline abstract_t">Delany DR, Johnston DR. Role of direct laryngoscopy and bronchoscopy in recurrent croup. Otolaryngol Head Neck Surg 2015; 152:159.</a></li><li><a class="nounderline abstract_t">Rankin I, Wang SM, Waters A, et al. The management of recurrent croup in children. J Laryngol Otol 2013; 127:494.</a></li><li><a class="nounderline abstract_t">Jabbour N, Parker NP, Finkelstein M, et al. Incidence of operative endoscopy findings in recurrent croup. Otolaryngol Head Neck Surg 2011; 144:596.</a></li><li><a class="nounderline abstract_t">Chun R, Preciado DA, Zalzal GH, Shah RK. Utility of bronchoscopy for recurrent croup. Ann Otol Rhinol Laryngol 2009; 118:495.</a></li><li><a class="nounderline abstract_t">Hiebert JC, Zhao YD, Willis EB. Bronchoscopy findings in recurrent croup: A systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol 2016; 90:86.</a></li><li><a class="nounderline abstract_t">Hampton T, Ghazal Asswad R, Bhat J, et al. Recurrent croup is a good indicator of underlying paediatric airway issues: A 10-year retrospective cohort study of airway endoscopy. Ear Nose Throat J 2023; :1455613231170087.</a></li><li><a class="nounderline abstract_t">Coughran A, Balakrishnan K, Ma Y, et al. The Relationship between Croup and Gastroesophageal Reflux: A Systematic Review and Meta-Analysis. Laryngoscope 2021; 131:209.</a></li></ol></div><div id="topicVersionRevision">Topic 6004 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/347921" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/347921" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nebulized racemic epinephrine by IPPB for the treatment of croup: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626194" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Glucocorticoids for croup in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385657" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A randomized trial of a single dose of oral dexamethasone for mild croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9613912" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nebulized budesonide and oral dexamethasone for treatment of croup: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709042" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A comparison of nebulized budesonide, intramuscular dexamethasone, and placebo for moderately severe croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An evidence-based approach to the evaluation and treatment of croup in children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7945599" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Racemic epinephrine in the treatment of laryngotracheitis: can we identify children for outpatient therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864472" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Safety and efficacy of nebulized racemic epinephrine in conjunction with oral dexamethasone and mist in the outpatient treatment of croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8806135" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Use of racemic epinephrine, dexamethasone, and mist in the outpatient management of croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696166" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The disposition of children with croup treated with racemic epinephrine and dexamethasone in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734400" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prospective randomized double-blind study comparing L-epinephrine and racemic epinephrine aerosols in the treatment of laryngotracheitis (croup).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628614" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nebulized budesonide is as effective as nebulized adrenaline in moderately severe croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19953656" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Croup presentations to emergency departments in Alberta, Canada: a large population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31442871" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Epidemiological analysis of croup in the emergency department using two national datasets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35970819" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Use of a Clinical Guideline and Orderset to Reduce Hospital Admissions for Croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24596395" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Viral croup: diagnosis and a treatment algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292873" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Variation in Inpatient Croup Management and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19682017" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 27 years of croup: an update highlighting the effectiveness of 0.15 mg/kg of dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30988017" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hospital Course of Croup After Emergency Department Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30779245" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Management and outcomes of patients presenting to the emergency department with croup: Can we identify which patients can safely be discharged from the emergency department?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36751889" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Predictors of Inpatient Racemic Epinephrine Use in Patients Admitted With Croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24584978" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inpatient hospitalizations for croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31342466" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inpatient use of racemic epinephrine for children admitted with croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26242923" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Inpatient Treatment after Multi-Dose Racemic Epinephrine for Croup in the Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855994" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Humidified air inhalation for treating croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23114231" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30371952" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Heliox for croup in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27029657" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Intensive care management of children intubated for croup: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34846064" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Variation in Dexamethasone Dosing and Use Outcomes for Inpatient Croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31076458" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Predictors of Symptom Rebound in Critically Ill Patients With Croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2654865" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Steroid treatment of laryngotracheitis: a meta-analysis of the evidence from randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1356176" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Placebo-controlled trial of prednisolone in children intubated for croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31033996" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Glucocorticoids for Croup in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649914" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Oral and inhaled steroids in croup: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16620410" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25236311" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Cochrane Library and safety of systemic corticosteroids for acute respiratory conditions in children: an overview of reviews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24943696" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Psychiatric adverse effects of pediatric corticosteroid use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375615" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375615" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Safety of corticosteroids in young children with acute respiratory conditions: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616215" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oral dexamethasone for mild croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8634728" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Outpatient treatment of croup with nebulized dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8660054" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Steroids for intubated croup masking airway haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732953" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effectiveness of oral or nebulized dexamethasone for children with mild croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732953" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Effectiveness of oral or nebulized dexamethasone for children with mild croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8688774" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of a small single dose of oral dexamethasone for outpatient croup: a double blind placebo controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8649915" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305661" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison between single-dose oral prednisolone and oral dexamethasone in the treatment of croup: a randomized, double-blinded clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of a small dose of oral dexamethasone in croup</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31416827" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092872" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The comparative effectiveness of prednisolone and dexamethasone for children with croup: a community-based randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15013613" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A comparison of nebulized budesonide, and intramuscular, and oral dexamethasone for treatment of croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15942511" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Budesonide offers no advantage when added to oral dexamethasone in the treatment of croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632929" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The efficacy of nebulized budesonide in dexamethasone-treated outpatients with croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212395" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The effectiveness of local corticosteroids therapy in the management of mild to moderate viral croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16912619" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Oral betamethasone versus intramuscular dexamethasone for the treatment of mild to moderate viral croup: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516095" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effects of inhaled fluticasone propionate administered with metered dose inhaler and spacer in mild to moderate croup: a negative preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24114291" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Nebulized epinephrine for croup in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30878411" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of low-dose nebulized epinephrine as treatment for croup: A randomized, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779773" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Viral croup: current diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1096594" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Treatment of laryngotracheobronchitis (croup). Use of intermittent positive-pressure breathing and racemic epinephrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7841729" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inhalation of racemic adrenaline in the treatment of mild and moderately severe croup. Clinical symptom score and oxygen saturation measurements for evaluation of treatment effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6754899" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Racemic epinephrine in the treatment of croup: nebulization alone versus nebulization with intermittent positive pressure breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10390295" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pediatric myocardial infarction after racemic epinephrine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/466564" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of helium--oxygen mixtures in the management of severe viral and post-intubation croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9835482" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effect of heliox on croup: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389294" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A randomized comparison of helium-oxygen mixture (Heliox) and racemic epinephrine for the treatment of moderate to severe croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Heliox as mild treatment for croup [Heliox como tratamiento del crup moderado]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208675" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A randomized controlled trial of mist in the acute treatment of moderate croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537737" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Controlled delivery of high vs low humidity vs mist therapy for croup in emergency departments: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4683316" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Physical properties of sputum. IV. Effects of 100 per cent humidity and water mist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4903094" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mist therapy: rationale and practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6614970" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Moist air in the treatment of laryngotracheitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/857235" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The respiratory mechanism of aerosol inhalation in the treatment of partial airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/857235" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The respiratory mechanism of aerosol inhalation in the treatment of partial airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/857235" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The respiratory mechanism of aerosol inhalation in the treatment of partial airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2121944" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transcutaneous carbon dioxide pressure for monitoring patients with severe croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24335668" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Duration of symptoms of respiratory tract infections in children: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2034489" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Review of intubation in severe laryngotracheobronchitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9115533" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Acute pulmonary edema in a child with spasmodic croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20018389" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Laryngotracheobronchitis complicated by spontaneous pneumomediastinum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716164" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Out-of-hospital cardiopulmonary arrest in children with croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1889864" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The need for intubation in serious upper respiratory tract infection in pediatric patients (a retrospective study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22588730" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Atypical croup: association with airway lesions, atopy, and esophagitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25409938" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Role of operative airway evaluation in children with recurrent croup: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389322" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Role of direct laryngoscopy and bronchoscopy in recurrent croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23544702" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The management of recurrent croup in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493242" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Incidence of operative endoscopy findings in recurrent croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19708488" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Utility of bronchoscopy for recurrent croup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27729160" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Bronchoscopy findings in recurrent croup: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37141917" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Recurrent croup is a good indicator of underlying paediatric airway issues: A 10-year retrospective cohort study of airway endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32040207" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The Relationship between Croup and Gastroesophageal Reflux: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
